MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

NCT03971071 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 620

Last updated 2025-09-19

Study results available
· View outcomes & findings →

Summary

Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnosed with medication overuse headache (MOH).

Conditions

  • Migraine Headache

Interventions

DRUG

Erenumab 70 mg

Erenumab once every 4 weeks. Subcutaneous injection.

DRUG

Erenumab 140 mg

Erenumab once every 4 weeks. Subcutaneous injection.

DRUG

Placebo

Placebo once every 4 weeks. Subcutaneous injection.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-07
Primary Completion
2022-12-01
Completion
2023-06-13
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Czechia
  • Finland
  • France
  • Hungary
  • Italy
  • Poland
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03971071 on ClinicalTrials.gov